USPTO serial 90674894
LUXZYLA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- HILLIARD, JESSICA LYNN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LUXZYLA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mary Frances Love
Mary Frances Love MUNCY, GEISSLER, OLDS & LOWE, P.C.125 S. Royal St.Alexandria, VA 22314UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents for the treatment of disorders of the metabolism and digestive system; pharmaceutical agents for the treatment of lysosomal storage disorders and lysosomal storage diseases; pharmaceutical agents for the treatment of lysosomal storage disorders and lysosomal storage diseases all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; pharmaceutical agents for the treatment of Wilson's Disease; pharmaceutical agents for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; pharmaceutical preparations for the treatment of disorders of the metabolism and digestive system; pharmaceutical preparations for the treatment of lysosomal storage disorders and lysosomal storage diseases; pharmaceutical preparations for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; pharmaceutical preparations for the treatment of Wilson's Disease; pharmaceutical preparations for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; pharmaceuticals for the treatment of disorders of the metabolism and digestive system, pharmaceuticals for the treatment of lysosomal storage disorders and lysosomal storage diseases; pharmaceuticals for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; pharmaceuticals for the treatment of Wilson's Disease; pharmaceuticals for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; Veterinary pharmaceutical preparations for treatment of disorders of the metabolism and digestive system; veterinary pharmaceutical preparations, namely, antioxidants; Veterinary pharmaceutical preparations, namely, pain relief medications; Veterinary pharmaceutical preparations for treatment of chronic illnesses; Veterinary pharmaceutical preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic foods adapted for medical or veterinary use; dietary supplements for humans and animals supplements for the treatment of disorders of the metabolism and digestive system; Dietary supplements for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibles, vapors, gases, mists, creams, gels and patches; Dietary supplements for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; biological preparations for the treatment of disorders of the metabolism and digestive system; biological preparations for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; biological preparations for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; chemical preparations for medical purposes, namely, for the treatment of disorders of the metabolism and digestive system; chemical preparations for medical purposes, namely, for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibles, vapors, gases, mists, creams, gels and patches; chemical preparations for medical purposes, namely, for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches for use in pharmaceuticals; drug delivery agents in the form of capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches for use in the treatment of disorders of the metabolism and digestive system; drug delivery agents in the form of capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches for use in the treatment of lysosomal storage disorders and lysosomal storage diseases; drug delivery agents in the form of capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches for use in the treatment of Wilson's Disease; Pharmaceutical preparations in the form of drugs and medicines for the treatment of disorders of the metabolism and digestive system; Pharmaceutical preparations in the form drugs and medicines for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibles, vapors, gases, mists, creams, gels and patches; Pharmaceutical preparations in the form drugs and medicines for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; Pharmaceutical preparations in the form of drugs for the treatment of rare diseases, in particular for the treatment of disorders of the metabolism and digestive system; Pharmaceutical preparations in the form of drugs for the treatment of rare diseases, in particular for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; Pharmaceutical preparations in the form of drugs for the treatment of rare diseases, in particular for Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibles, vapors, gases, mists, creams, gels and patches; enzyme preparations for medical purposes; enzyme preparations for medical purposes for the treatment of disorders of the metabolism and digestive system; enzyme preparations for medical purposes the treatment of lysosomal storage disorders and lysosomal storage diseases; enzyme preparations for medical purposes the treatment of Wilson's Disease; medical enzyme preparations for medical purposes in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; enzyme preparations for veterinary purposes; medical preparations for the treatment of disorders of the metabolism and digestive systems; medical preparations for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; medical preparations for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches; medical preparations for the treatment of disorders of the metabolism and digestive system, medicines for the treatment of lysosomal storage disorders and lysosomal storage diseases, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches medicines for the treatment of Wilson's Disease, all in the form of liquids, solutions, suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersibiles, vapors, gases, mists, creams, gels and patches | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 22, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 22, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 19, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 19, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 22, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 22, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2023 | ALIE | ASSIGNED TO LIE | — |
| Apr 7, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 7, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 7, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 7, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 11, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 30, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 30, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 30, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 30, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 17, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 5, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 5, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 5, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 3, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 30, 2021 | NWAP | NEW APPLICATION ENTERED | — |